A Pilot Randomized Study to Assess the Effect and Safety Profile of Thymoglobulin in Primary Cardiac Transplant Recipients: A 12-month, Single Center, Randomized, Open-label Study of Efficacy Comparing Immediate Treatment With and Without Thymoglobulin 1.5 mg/kg/d for 5 Consecutive Days in Heart Transplant Recipients
Latest Information Update: 21 Nov 2022
At a glance
- Drugs Antithymocyte globulin (Primary) ; Methylprednisolone; Mycophenolate mofetil; Mycophenolate mofetil; Prednisone; Sirolimus; Tacrolimus; Tacrolimus
- Indications Heart transplant rejection
- Focus Therapeutic Use
- 11 Nov 2022 Planned End Date changed from 31 Oct 2024 to 31 Oct 2025.
- 20 Oct 2021 Planned End Date changed from 30 Jun 2021 to 31 Oct 2024.
- 20 Oct 2021 Planned primary completion date changed from 22 Jun 2021 to 31 Oct 2024.